Physician profile
David Farmer
NPI 1619985041
$6,209.29
in general payments reported to CMS, 2019-2025
45 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,385 · 2022: $1,230 · 2023: $1,711 · 2024: $1,639 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $783.40 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $766.86 | 2021-2024 | |
| Novo Nordisk INC | $559.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $378.92 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $354.51 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Corium, LLC | $329.17 | 2022-2024 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $244.81 | 2023-2025 | Sunosi, Auvelity |
| Pfizer INC. | $203.19 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.75 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.46 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.04 | 2021-2024 | Xifaxan, Trulance |
| Lundbeck LLC | $157.62 | 2024-2025 | Rexulti, Brintellix |
| Collegium Pharmaceutical, INC. | $139.40 | 2023-2024 | Belbuca, Xtampza |
| Hikma Pharmaceuticals USA | $138.66 | 2021-2023 | Mitigare, Ryaltris |
| Sanofi-Aventis U.S. LLC | $123.61 | 2021-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.